相关实验视频

Updated: Jul 13, 2025

Inhibition of Aspergillus flavus Growth and Aflatoxin Production in Transgenic Maize Expressing the α-amylase Inhibitor from Lablab purpureus L.

Inhibition of Aspergillus flavus Growth and Aflatoxin Production in Transgenic Maize Expressing the α-amylase Inhibitor from Lablab purpureus L.

Published on: February 15, 2019

探索双黄对α-葡萄糖酶的抑制性质;计算和实验方法

Morteza Sadeghi¹, Mehran Miroliaei¹, Mustafa Ghanadian²

¹Faculty of Biological Science and Technology, Department of Cell and Molecular Biology & Microbiology, University of Isfahan, Isfahan, Iran.

International journal of biological macromolecules

|October 14, 2023

概括

斯特里克诺比弗拉通过抑制α-葡萄糖酶,显示出对治疗糖尿病的强大潜力. 这种双黄与酶中的关键氨基酸相互作用,改变其构造和催化活性,从而产生潜在的治疗益处.

科学领域:

生物化学生物化学
药理学药理学是指药理学的学科.
计算化学计算化学

背景情况:

双黄 (BFs) 是多,可以通过抑制α-葡萄糖酶来控制糖尿病 (DM).
阿尔法-葡萄糖酶抑制是通过减少小肠中的葡萄糖吸收来管理DM中血糖水平升高的关键策略.
BFs和α-葡萄糖酶之间的精确相互作用需要进一步研究.

研究的目的:

为了识别具有显著的α-葡萄糖酶抑制活性的双黄.
为了研究选择的BF与α-葡萄糖酶的结合亲和力和分子相互作用.
评估BFs作为糖尿病治疗药物的潜力.

主要方法:

基于对接的虚拟选被用来评估18个选定的BF与α-glucosidase的结合亲和力.
用分子动力学模拟 (MDs) 来分析alpha-glucosidase-BF复合物的动态活性和稳定性.
为了描述抑制机制,进行了体外动力学研究和二次结构分析.

主要成果:

斯特里克诺比弗拉在测试的BF中表现出最高的α-葡萄糖酶抑制活性.
分子对接揭示了基和关键残留物 (Arg315,Phe303) 之间通过阴离子-π和π-π堆叠的相互作用.
动力学研究将基诺比弗拉归类为混合类型的抑制剂,导致酶的显著构造变化.

结论:

斯特里克诺比弗拉通过抑制α-葡萄糖酶,显示出作为糖尿病治疗候选者的巨大潜力.
观察到的相互作用和形状变化突出显示了斯特诺比弗拉的作用机制.
需要进一步的体外和体内研究来证实基在治疗糖尿病中的疗效.

关键词:

双黄类化合物双黄类化合物糖尿病是一种糖尿病.混合抑制抑制的混合抑制斯特里克诺比弗拉是一种固醇.α-葡萄糖化酶的使用.

更多相关视频

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota

Structural Biology and Analytical Chemistry Approaches for Characterizing C-Glycoside Metabolic Enzymes in Human Gut Microbiota

Published on: May 23, 2025

Systematic Approach to Identify Novel Antimicrobial and Antibiofilm Molecules from Plants' Extracts and Fractions to Prevent Dental Caries

Systematic Approach to Identify Novel Antimicrobial and Antibiofilm Molecules from Plants' Extracts and Fractions to Prevent Dental Caries

Published on: March 31, 2021

相关概念视频

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Enzyme Inhibition

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.